Short Interest in INVO Fertility, Inc (NASDAQ:IVF) Declines By 37.8%

INVO Fertility, Inc (NASDAQ:IVF) was the target of a significant decline in short interest in the month of January. As of January 15th, there was short interest totaling 41,109 shares, a decline of 37.8% from the December 31st total of 66,048 shares. Approximately 1.7% of the shares of the company are short sold. Based on an average daily volume of 178,991 shares, the short-interest ratio is currently 0.2 days. Based on an average daily volume of 178,991 shares, the short-interest ratio is currently 0.2 days. Approximately 1.7% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of INVO Fertility in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On INVO Fertility

A hedge fund recently bought a new stake in INVO Fertility stock. Citadel Advisors LLC bought a new position in shares of INVO Fertility, Inc (NASDAQ:IVF) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned approximately 1.19% of INVO Fertility as of its most recent SEC filing. Institutional investors own 12.02% of the company’s stock.

INVO Fertility Trading Down 13.0%

Shares of IVF opened at $1.41 on Friday. INVO Fertility has a 1 year low of $0.71 and a 1 year high of $141.12. The stock has a 50 day simple moving average of $1.32 and a 200-day simple moving average of $6.31. The stock has a market cap of $3.37 million, a PE ratio of 0.00 and a beta of 2.60.

About INVO Fertility

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.